Current/ Expected Orderbook/ Pending Orders?

The order pipeline for Oriental Aromatics' fragrance division is described as healthy. Both domestic FMCG clients and international buyers have provided encouraging forecasts. The company's creative teams are actively working on multiple new fragrance briefs expected to translate into business. Growth expectations are supported by new capacities coming online in Vadodara and Mahad Evermoss plant. The company anticipates improvement in margins as product mix shifts toward more value-added ingredients and pricing normalizes. Overall, management expressed confidence about the growth trajectory an

Any current/future new fundraising through debt or equity?

The company has not explicitly mentioned any current or upcoming fundraising plans through debt or equity in the provided transcript. Management highlighted that their long-term debt primarily finances the brownfield project in Baroda and the greenfield project (Mahad), which is in the sales growth and stabilization phase. Working capital debt has increased strategically due to maintaining higher inventories and receivables; this is being managed and reviewed. There is no mention of new debt or equity raising efforts; focus is on stabilizing and ramping up existing projects. Any updates on pot

Any current/future capex/capital investment/strategic investment?

The Mahad greenfield facility has scope for future expansions with available land for three more plants similar in size to the existing Evermoss plant, subject to environmental clearance. Current focus is on stabilization, capacity utilization, and profitable growth before further expansions. Future CAPEX will be targeted and undertaken only when very specific strategic opportunities arise. The Vadodara hydrogenation unit, commissioned in July 2024, is already contributing to new products and efficiency gains. Overall, expansions depend on market conditions and specific opportunity-driven proj

Future growth expectations in sales/revenue/volumes?

Focus on ramping up Mahad greenfield facility to optimal capacity over next few quarters. New hydrogenation unit at Vadodara commissioned in July 2024 contributes to new products and efficiency. Strategy emphasizes quality growth, prioritizing profitability and long-term value over short-term volume gains. Specialty aroma ingredients division expected to grow with new product launches and global approvals. Expansion projects underpin confidence in long-term demand and global market share capture. Expect turnover from Mahad expansion at conservative ratio of 1.4 to 1.5 times investment. Capacit

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is cautiously optimistic about FY'26 and beyond, focusing on profitable growth and margin improvement. EBITDA guidance remains conservatively at 10% to 11%, with a possibility to improve margins if opportunities arise. Specialty aroma ingredients and fragrance divisions are expected to grow, with new capacities (Vadodara hydrogenation, Mahad Evermoss) coming online to meet increasing demand. Margin improvement is anticipated as product mix shifts to more value-added ingredients and pricing normalizes. Camphor segment shows early signs of price stabilization and volume uptic

IN US

Sale is live|00:00:00left today

Oriental Aromatics LtdQ1 FY25Chemicals & Petrochemicals

Oriental Aromatics Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹324P/E: 1440.7Market Cap: ₹1.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Focus on ramping up Mahad greenfield facility to optimal capacity over next few quarters.
→New hydrogenation unit at Vadodara commissioned in July 2024 contributes to new products and efficiency.
→Strategy emphasizes quality growth, prioritizing profitability and long-term value over short-term volume gains.
→Specialty aroma ingredients division expected to grow with new product launches and global approvals.
→Expansion projects underpin confidence in long-term demand and global market share capture.
→Expect turnover from Mahad expansion at conservative ratio of 1.4 to 1.5 times investment.
→Capacity for further expansion at Mahad with land bank for up to three more plants.
→New customer acquisitions and deepening engagement with FMCG clients to boost sales.
→Fragrance division identified as a key growth driver despite overall economic headwinds.
→Cautiously optimistic about improving margins and sales in camphor and terpene chemicals segment.
→Strategic inventory build-up aimed at capturing value as raw material prices rise.

Margin guidance

Category 3

→The company is cautiously optimistic about FY'26 and beyond, focusing on profitable growth and margin improvement.
→EBITDA guidance remains conservatively at 10% to 11%, with a possibility to improve margins if opportunities arise.
→Specialty aroma ingredients and fragrance divisions are expected to grow, with new capacities (Vadodara hydrogenation, Mahad Evermoss) coming online to meet increasing demand.
→Margin improvement is anticipated as product mix shifts to more value-added ingredients and pricing normalizes.
→Camphor segment shows early signs of price stabilization and volume uptick, poised for margin improvement in FY’26.
→Mahad greenfield project is in sales growth & stabilization phase; turnover expected at a conservative 1.4x to 1.5x investment, with ramp-up expected post approvals.
→Strategic inventory buildup and customer receivables are expected to positively impact working capital and future earnings.
→Overall, the company aims for consistent growth with a focus on stable and profitable operations.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has not explicitly mentioned any current or upcoming fundraising plans through debt or equity in the provided transcript.
→Management highlighted that their long-term debt primarily finances the brownfield project in Baroda and the greenfield project (Mahad), which is in the sales growth and stabilization phase.
→Working capital debt has increased strategically due to maintaining higher inventories and receivables; this is being managed and reviewed.
→There is no mention of new debt or equity raising efforts; focus is on stabilizing and ramping up existing projects.
→Any updates on potential financing activities would likely be communicated to investors in the future.

Order book

Yes

→The order pipeline for Oriental Aromatics' fragrance division is described as healthy.
→Both domestic FMCG clients and international buyers have provided encouraging forecasts.
→The company's creative teams are actively working on multiple new fragrance briefs expected to translate into business.
→Growth expectations are supported by new capacities coming online in Vadodara and Mahad Evermoss plant.
→The company anticipates improvement in margins as product mix shifts toward more value-added ingredients and pricing normalizes.
→Overall, management expressed confidence about the growth trajectory and the ability to convert the current order book into business.

Capex plans

Yes

→The Mahad greenfield facility has scope for future expansions with available land for three more plants similar in size to the existing Evermoss plant, subject to environmental clearance.
→Current focus is on stabilization, capacity utilization, and profitable growth before further expansions.
→Future CAPEX will be targeted and undertaken only when very specific strategic opportunities arise.
→The Vadodara hydrogenation unit, commissioned in July 2024, is already contributing to new products and efficiency gains.
→Overall, expansions depend on market conditions and specific opportunity-driven projects rather than broad-scale immediate CAPEX.
→Strategy emphasizes cautious, efficient use of capital aligned with sales growth and stabilization, avoiding unnecessary large-scale investments at present.

How does Oriental Aromatics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Oriental Aromatics Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Oriental Aromatics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio